20(S)‎-Ginsenoside Rg3 Protects Kidney from Diabetic Kidney Disease via Renal Inflammation Depression in Diabetic Rats

Abstract EN

20(S)-Ginsenoside Rg3 (20(S)-Rg3) has been shown to induce apoptosis by interfering with several signaling pathways.

Furthermore, it has been reported to have anticancer and antidiabetic effects.

In order to detect the protective effect of 20(S)-Rg3 on diabetic kidney disease (DKD), diabetic rat models which were established by administering high-sugar, high-fat diet combined with intraperitoneal injection of streptozotocin (STZ), and age-matched wild-type (WT) rat were given 20(S)-Rg3 for 12 weeks, with three groups: control group (normal adult rats with saline), diabetic group (diabetic rats with saline), and 20(S)-Rg3 treatment group (diabetic rats with 20(S)-Rg3 (10 mg/kg body weight/day)).

The biochemical indicators and the changes in glomerular basement membrane and mesangial matrix were detected.

TUNEL staining was used to detect glomerular and renal tubular cell apoptosis.

Immunohistochemical staining was used to detect the expression of fibrosis factors and inflammation factors in rat kidney tissues.

Through periodic acid-Schiff staining, we observed that the change in renal histology was improved and renal tubular epithelial cell apoptosis decreased significantly by treatment with 20(S)-Rg3.

Plus, the urine protein decreased in the rats with the 20(S)-Rg3 treatment.

Fasting blood glucose, creatinine, total cholesterol, and triglyceride levels in the 20(S)-Rg3 treatment group were all lower than those in the diabetic group.

Mechanistically, 20(S)-Rg3 dramatically downregulated the expression of TGF-β1, NF-κB65, and TNF-α in the kidney.

These resulted in a significant prevention of renal damage from the inflammation.

The results of the current study suggest that 20(S)-Rg3 could potentially be used as a novel treatment against DKD.